TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3284726
Drug: Neostigmine, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine, 0.5 mg, administered intramuscularly every third hour on the third day after laparotomy, until passage of flatus or stools or a total of three injections
Study: 31241854
Drug: Intradermal PRP
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal PRP alone
Study: 31241854
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with subcision followed by PRP injection
Study: 25497264
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment in diabetic patients
Study: 25497264
Drug: Non-insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-insulin treatment in diabetic patients
Study: 24432627
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate liquid (10 ml, bid) and vitamin E (100 mg, bid) for 3 months (Control)
Study: 18156535
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg oral dexamethasone
Study: 2931831
Drug: Baclofen (30-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (30-80 mg daily)
Study: 27881108
Drug: Blended smoking
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended smoking cessation treatment (5 online sessions, 5 face-to-face sessions)
Study: 27881108
Drug: Face-to-face smoking
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face smoking cessation treatment (10 face-to-face sessions)
Study: 24549163
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of autologous bone marrow mononuclear cells (BMCs)
Study: 20925951
Drug: Fractionated stereotactic
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated stereotactic radiotherapy (FSRT) with a total dose of 36 Gy in single doses of 2 Gy
Study: 2710173
Drug: Calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium acetate (4.4 g, 25 mmol of calcium)
Study: 30924600
Drug: Collagen matrix
Normalized name: Omeza Collagen Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen matrix implant (Ologen®; OLO)
Study: 27889320
Drug: Two intraoperative,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two intraoperative, intravenous doses (IOIO)
Study: 27889320
Drug: One preoperative
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One preoperative plus two intraoperative, intravenous doses (POIOIO)
Study: 23025424
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of the dosing aid
Study: 23025424
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of the dosing aid with the drop guider
Study: 23025424
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of the dosing aid together with patient education
Study: 23025424
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of the dosing aid and drop guider together with patient education
Study: 21736730
Drug: Brief Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Intervention plus Cognitive Behavioral Treatment (CBT)
Study: 21736730
Drug: Brief Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Intervention plus nutritional supplements of seal oil
Study: 21736730
Drug: Brief Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Intervention plus nutritional supplements of soy oil
Study: 16556690
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (SC)
Study: 17294445
Drug: LHT+IT-DC (intratumoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHT+IT-DC (intratumoral injection of autologous immature dendritic cells after local hyperthermia)
Study: 17294445
Drug: IT-DC (intratumoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT-DC (intratumoral injection of autologous immature dendritic cells without local hyperthermia)
Study: 15266633
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with 860 nm gallium/aluminum/arsenide laser at a dosage of 6 J/cm2, treated three times per week for 5 weeks.
Study: 15266633
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser treatment, treated three times per week for 5 weeks.
Study: 29661497
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy with irinotecan (CPT‐11; 60 mg/m2 intravenously on days 1 and 8) and nedaplatin (NDP; 80 mg/m2 intravenously on day 1), administered within 6 weeks after surgery and repeated every 28 days for up to 5 cycles.
Study: 24846652
Drug: AMG 157
Normalized name: AMG 157
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMG 157 (700 mg)
Study: 20183666
Drug: Treatment-related costs
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related costs
Study: 15662232
Drug: Grape-seed polyphenols
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape-seed polyphenols (1000 mg/day)
Study: 15662232
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamin C and grape-seed polyphenols
Study: 16189176
Drug: GH administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH administration alone
Study: 31263727
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic Acid (HA) injection
Study: 10549114
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic Acid (HA) therapy
Study: 7723158
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (maintaining hemoglobin values between 100 and 120 g/L)
Study: 7723158
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (maintaining hemoglobin values between 70 and 90 g/L)
Study: 6119940
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg of diazepam
Study: 6119940
Drug: 3 X
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 10(‐1) mg/kg of fentanyl
Study: 26802643
Drug: SQ grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ grass sublingual immunotherapy (SLIT) tablet
Study: 21652583
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) chemotherapy with PBSCs
Study: 21652583
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (SD) chemotherapy
Study: 18971768
Drug: Hypnotic induction
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic induction with analgesic suggestion
Study: 18971768
Drug: Hypnotic induction
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic induction without analgesic suggestion
Study: 18971768
Drug: Merged hypnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merged hypnosis groups (hypnotic induction with and without analgesic suggestion)
Study: 14641849
Drug: Intradomestic residual
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradomestic residual spraying of lambda‐cyhalothrin, E.C., 25 mg/m2
Study: 14641849
Drug: Spatial fogging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spatial fogging of fenitrothion around the houses at 30 g/ha
Study: 14641849
Drug: Intradomestic residual
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradomestic residual spraying of lambda‐cyhalothrin three times a year, at a dose slightly greater than 25 mg/m2
Study: 11200148
Drug: Oral fluoropyrimidines
Normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral fluoropyrimidines (UFT plus leucovorin, capecitabine, eniluracil plus oral 5‐FU)
Study: 8975963
Drug: Erythromycin lactobionate
Normalized name: Erythromycin Lactobionate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin lactobionate 7 mg per kg
Study: 1736348
Drug: Budesonide enema
Normalized name: budesonide Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide enema (2 mg/100 ml)
Study: 6342163
Drug: Gentamicin-containing steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin-containing steroid ointment
Study: 29679749
Drug: SC peginterferon
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC peginterferon beta-1a 125 mcg every two weeks
Study: 29679749
Drug: SC interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC interferon beta-1a 44 mcg three times per week
Study: 26937774
Drug: Energy drink
Normalized name: Boost Energy Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy drink (Red Bull, 500 ml)
Study: 22993936
Drug: Cycloferon in
Normalized name: Cicloferon
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycloferon in the complex treatment
Study: 17765564
Drug: Diluted Sanofi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted Sanofi Pasteur smallpox vaccine
Study: 16324343
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg every night (Group B)
Study: 16324343
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg every night (Group C)
Study: 16324343
Drug: Basal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal treatment (Group A)
Study: 10197569
Drug: Solid foods
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid foods (SF) twice daily from 4 to 6 months
Study: 90217
Drug: Bromocriptine 2.5
Normalized name: bromocriptine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 2.5 mg twice a day
Study: 25808169
Drug: D-cycloserine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (50 mg) and Placebo (PBO)
Study: 22404704
Drug: Quetiapine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (300 or 600 mg/day)
Study: 22820896
Drug: Orlistat 60
Normalized name: orlistat 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 60 mg
Study: 9498448
Drug: Finlay Institute
Normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finlay Institute (Havana) vaccine
Study: 9498448
Drug: National Institute
Normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: National Institute of Public Health (Oslo) vaccine
Study: 7849954
Drug: Perflubron emulsion
Normalized name: PERFLUBRON
DrugBank: Perflubron (DB05791)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perflubron emulsion (0.15 to 0.50 mL) administered by subcutaneous injection
Study: 7849954
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of massage to the injection site
Study: 3240893
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with Ditropan 5 mg t.i.d. for 6 weeks prior to surgery (n = 21)
Study: 3240893
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (n = 18) with no prior treatment for bladder instability
Study: 3240893
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (n = 18)
Study: 28473118
Drug: Continued thienopyridine
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued thienopyridine plus aspirin therapy for an additional 18 months
Study: 18048857
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of BoNT‐A (BOTOX 100 U total) and intraarticular injection of normal saline
Study: 18048857
Drug: Intraarticular injection
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injection of TA (40 mg) and intramuscular injection of normal saline
Study: 16863563
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) herbal formula containing 11 herbs
Study: 12641502
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic therapy (metronidazole 300 mg, clarithromycin 250 mg, and amoxicillin 500 mg, given four times daily for 2 weeks)
Study: 15545314
Drug: Flurbiprofen microparticle
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen microparticle formulation (3.125 mg, 6.25 mg, 12.5 mg, 25 mg, or 50 mg)
Study: 15545314
Drug: Flurbiprofen microparticle
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen microparticle formulation (12.5 mg and higher doses)
Study: 2314826
Drug: Very-high-dose cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Very-high-dose cisplatin (40 mg/m2/day for 5 days)
Study: 2314826
Drug: Standard-high-dose cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-high-dose cisplatin (either a single dose of 100 or 20 mg/m2/day for 5 days)
Study: 303498
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of minocycline twice a day
Study: 303498
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of minocycline twice a day
Study: 18093505
Drug: Calendar reminder
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calendar reminder of medication taking
Study: 17352866
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal treatment)
Study: 11448321
Drug: 0.03% AGN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% AGN 192024 once daily
Study: 11448321
Drug: 0.003% AGN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.003% AGN 192024 once daily
Study: 11448321
Drug: 0.01% AGN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% AGN 192024 once daily
Study: 11448321
Drug: 0.03% AGN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% AGN 192024 twice daily
Study: 10405567
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with alteplase (r-TPA), aspirin, glyceryl trinitrate
Study: 10405567
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy without reperfusion
Study: 19545481
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list for therapy
Study: 25869840
Drug: Microdosing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdosing of (14)C-hRESCAP at 53 μg
Study: 25869840
Drug: Therapeutic doses
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic doses of hRESCAP (up to 5.3 mg)
Study: 21880193
Drug: Salmeterol/Fluticasone Propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/Fluticasone Propionate (SAL/FP) 50/250 μg, administered 2 inhalations BID for 2 weeks
Study: 21880193
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate (FP) 250 μg, administered 2 inhalations BID for 2 weeks
Study: 21880193
Drug: Salmeterol/Fluticasone Propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/Fluticasone Propionate (SAL/FP) 50/250 μg
Study: 21880193
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate (FP) 250 μg
Study: 15089806
Drug: Moxonidine 0.4
Normalized name: moxonidine 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 0.4 mg orally
Study: 9863079
Drug: Combined acupuncture-drug
Normalized name: antibiotics in combination with other drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined acupuncture-drug anesthesia (dolantin 25 mg and droperidol 2.5 mg administered intravenously, with acupuncture stimulation at Neiguan (P6) and Hegu (LI4) for 30 minutes).
Study: 9863079
Drug: 5% procaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% procaine combined with drug anesthesia (control group).
Study: 7868672
Drug: Reduced glutathione
Normalized name: Reduced glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced glutathione therapy
Study: 3280220
Drug: Verapamil 80
Normalized name: verapamil 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 80 mg t.i.d. for one week
Study: 3280220
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg t.i.d. for one week
Study: 3280220
Drug: Diltiazem 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 80 mg t.i.d. for one week
Study: 3280220
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg t.i.d. for one week
Study: 3280220
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of both drugs
Study: 3280220
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of diltiazem
Study: 30126709
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor-1 (IGF-1)
Study: 17393021
Drug: Enoxaparin 4,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 4,000 IU once daily
Study: 17393021
Drug: Tinzaparin 4,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin 4,500 IU once daily
Study: 12324912
Drug: Q(a) (reduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q(a) (reduction of 1,000 mL/min)
Study: 9807203
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (tamoxifen) in postmenopausal patients
Study: 9807203
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (tamoxifen) in reproductive group
Study: 7657415
Drug: Caffeine 0
Normalized name: caffeine 0.65 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 0 mg.kg body weight-1 (placebo)
Study: 7657415
Drug: Caffeine 5
Normalized name: caffeine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 5 mg.kg body weight-1
Study: 7657415
Drug: Caffeine 9
Normalized name: multivit,calcium,min/ferrous fum/folic acid/guarana/caffeine 9 mg iron-400 mcg-200 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 9 mg.kg body weight-1
Study: 7657415
Drug: Caffeine 13
Normalized name: caffeine 13 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 13 mg.kg body weight-1
Study: 2719903
Drug: Oral aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aqueous solution
Study: 2719903
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release oral tablet (MST-Continus)
Study: 2719903
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release buccal tablet
Study: 27569351
Drug: Naftopidil 75
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 75 mg for 8 weeks
Study: 27569351
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg and Solifenacin 5 mg for 8 weeks
Study: 24844611
Drug: High-Ca group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Ca group (600 mg of calcium per day)
Study: 24844611
Drug: Low-Ca group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Ca group (300 mg of calcium per day)
Study: 24844611
Drug: Mid-Ca group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-Ca group (300 mg of calcium per day)
Study: 14559319
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg daily of Se as selenomethionine (SeMet) for 4 weeks
Study: 10965636
Drug: Systemic-behavioral family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic-behavioral family therapy (SBFT)
Study: 1479631
Drug: Substance abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance abuse treatment only
Study: 1479631
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control group receiving treatment for substance abuse and training in progressive muscle relaxation